Long-Term Outcomes of Recurrent Bulbar Urethral Stricture Treatment With the Optilume Drug-Coated Balloon: Five-Year Results From the ROBUST I Study
In this challenging cohort of men with failed prior endoscopic treatment, the Optilume DCB shows sustained improvement in subjective and objective voiding parameters at 5 years. Optilume is a safe and effective treatment option for appropriately selected men with recurrent bulbar urethral stricture who wish to avoid urethroplasty. Results are in line with the ROBUST III randomized controlled trial that will continue follow-up through 5 years.
Authors
- Sean P. Elliott (ORCID: https://orcid.org/0000-0002-5280-2449)
- Gustavo Espino (ORCID: https://orcid.org/0000-0001-5617-5705)
- Rafael Estrella
- Ramón Virasoro (ORCID: https://orcid.org/0000-0002-0339-723X)
- Merycarla Pichardo
- Jessica DeLong (ORCID: https://orcid.org/0000-0002-4938-6915)
- Ramón Rodríguez Lay
Institutions
- University of Minnesota (US)
- GC Systems (United States) (US)
- Universidad Especializada de las Américas (PA)
- Unión Médica Clínica Universitaria
- University of Colorado Colorado Springs (US)
Publication Details
- Journal
- The Journal of Urology
- Published
- 2024-08-30
- DOI
- https://doi.org/10.1097/ju.0000000000004229
- Citations
- 12
- Primary Topic
- Urological Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 6.42
Funders
- Boston Scientific Corporation